# US 2010/0143390 A1 · Polypeptides for inducing a protective immune response against staphylococcus epidermidis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0143390 A1
- Document ID: US20100143390A1
- Status: Published application
- Kind: A1
- Application number: 12/524,075
- Filed: 2008-01-18
- Published: 2010-06-10
- Earliest claimed: 2007-01-24
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: Annaliesa S. Anderson; Tessie McNeely; James C. Cook, III; William L. McClements; Donna L. Montgomery
- Web page: https://patentgrep.com/patent/US20100143390A1

## CPC

- A61K 39/085: Staphylococcus
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- A61K 2039/55505: {Inorganic adjuvants}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full-length S. epidermidis polypeptide. The full-length naturally occurring polypeptide is referred to herein as full-length ORF1319e. A His-tagged derivative of SEQ ID NO: 1 was found to produce a protective immune response against S. epidermidis.

## Claims

### Claim 1

A polypeptide immunogen comprising an amino acid sequence at least 85% identical to SEQ ID NO: 1, wherein said polypeptide provides protective immunity against S. epidermidis and the polypeptide does not have an amino acid sequence provided by SEQ ID NOs: 3 or 4.

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein said polypeptide consists of an amino acid sequence at least 94% identical to SEQ ID NO: 1.

### Claim 3 (depends on 2)

The polypeptide of claim 2, wherein said polypeptide consists essentially of SEQ ID NO: 1.

### Claim 4 (depends on 3)

The polypeptide of claim 3, wherein said polypeptide consists of an amino acid sequence of SEQ ID NO: 1 or methionine-SEQ ID NO: 1.

### Claim 5 (depends on 4)

The polypeptide of claim 4, wherein said polypeptide is substantially purified.

### Claim 6

An immunogen comprising an amino acid sequence at least 85% identical to SEQ ID NO: 1 and one or more additional regions or moieties covalently joined to said amino acid sequence at the carboxyl terminus or amino terminus, wherein each region or moiety is independently selected from a region or moiety having at least one of the following properties: enhances the immune response, facilitates purification, or facilitates polypeptide stability.

### Claim 7 (depends on 1)

A composition able to induce a protective immune response in a patient comprising an immunologically effective amount of the immunogen of claim 1 and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 7)

The composition of claim 7, wherein said composition further comprises an adjuvant.

### Claim 9 (depends on 1)

A nucleic acid comprising a recombinant gene comprising a nucleotide sequence encoding the polypeptide of claim 1.

### Claim 10 (depends on 9)

The nucleic acid of claim 9, wherein said nucleic acid is an expression vector.

### Claim 11 (depends on 9)

A recombinant cell comprising the nucleic acid of claim 9.

### Claim 12 (depends on 11)

A method of making a S. epidermidis polypeptide that provides protective immunity comprising the steps of:
(a) growing the recombinant cell of claim 11 under conditions wherein a polypeptide is expressed; and
(b) substantially purifying said polypeptide.

### Claim 13

A method of inducing a protective immune response in a patient comprising the step of administering to said patient an immunologically effective amount of immunogen comprising an amino acid sequence at least 85% identical to SEQ ID NO: 1.

### Claim 14 (depends on 13)

The method of claim 13, wherein said patient is a human.

### Claim 15 (depends on 13)

The method of claim 13, wherein said patient is treated prophylactically against S. epidermidis infection.

### Claim 16 (depends on 12)

A method of inducing a protective immune response in a patient comprising the step of administering to said patient an immunologically effective amount of a polypeptide made by the method of claim 12.
